

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sirnaomics Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2257)

CLARIFICATION ANNOUNCEMENT

Reference is made to the announcement of Sirnaomics Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated June 27, 2024 in relation to the completion of the Group’s STP707 Phase I clinical study (the “**Announcement**”). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

The Company would like to inform the shareholders and potential investors of the Company that the following inadvertent clerical errors were made in the Announcement, and would like to clarify that:

1. the sentence in the second paragraph on page 2 of the Announcement, that “Six dose levels (3mg/kg, 6mg/kg, 12mg/kg, 24mg/kg, 36mg/kg and 48mg/kg) were explored in ascending doses.” should be “Six dose levels (3mg, 6mg, 12mg, 24mg, 36mg and 48mg) were explored in ascending doses.”;
2. the sentence in the third paragraph on page 2 of the Announcement, that “The average days for stable disease for all 11 patients was 92 days, while 31 days for the 12mg/kg group, 65 days for 24mg/kg group and 112 days for 48mg/kg group, including one patient ongoing at 281 days.” should be “The average days for stable disease for all 11 patients with STP707 treatment was 92 days, while 31 days for the 12mg group, 65 days for 24mg group and 112 days for 48mg group, including one patient ongoing at 281 days.”; and

- the sentence in the first paragraph on page 3 of the Announcement, that “The maximum tolerated dose of STP707 for all 50 late-stage cancer patients was not reached even at 48mg/kg dosage level.” should be “The maximum tolerated dose of STP707 for all 50 late-stage cancer patients was not reached even at 48mg dosage level.”

Save as disclosed above, all other contents set out in the Announcement remain unchanged. This clarification announcement is supplemental to and should be read in conjunction with the Announcement.

By order of the Board
Sirnaomics Ltd.
Yang (Patrick) Lu
Chairman and Executive Director

Hong Kong, June 28, 2024

As at the date of this announcement, the Board comprises Dr. Yang Lu (alias Patrick Lu) and Dr. Xiaochang Dai as executive Directors, Mr. Mincong Huang and Mr. Jiankang Zhang as non-executive Directors, and Dr. Cheung Hoi Yu, Ms. Monin Ung and Ms. Shing Mo Han, Yvonne (alias Mrs. Yvonne Law) as independent non-executive Directors.